Skip to main content

Table 1 Patient characteristics according to diagnosis

From: Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer’s disease

 

Age, years

Sex, F/M (% female)

MMSE score at baseline

CSF Aβ42 (pg/ml)

CSF tau (pg/ml)

CSF p-tau (pg/ml)

Control subjects, n = 40

64.5 ± 8.2

19/21 (48%)

28.3 ± 1.7

1086 ± 161

228 ± 64

40 ± 9

MCI, n = 40

64.5 ± 8.1

19/21 (48%)

26.3 ± 2.3*

839 ± 297*

481 ± 256*

69 ± 33*

 sMCI, n = 23

63.7 ± 7.4

11/12 (48%)

26.7 ± 2.0

941 ± 306

338 ± 182

51 ± 21

 MCI-ADa, n = 14

65.6 ± 9.0

7/7 (50%)

25.9 ± 2.7

632 ± 84*,$

722 ± 186*,$

99 ± 28*,$

AD dementia, n = 40

64.6 ± 8.1

19/21 (48%)

21.6 ± 3.9*

640 ± 91*,‡,$

740 ± 433*,‡,$

94 ± 47*,‡,$

  1. Abbreviations: Aβ 42 Amyloid-β 1–42, AD Alzheimer’s disease, CSF Cerebrospinal fluid, MCI Mild cognitive impairment, MMSE Mini Mental State Examination, p-tau Tau phosphorylated at threonine 181, sMCI Stable mild cognitive impairment
  2. Data are displayed as mean ± SD unless otherwise indicated. Analysis of variance with post hoc Bonferroni corrections or chi-square tests were used when appropriate. CSF Aβ42, total tau, and p-tau were logarithmically transformed for the analyses because of skewed values; in the table, crude values are shown
  3. aMCI patients progressing to another form of dementia (n=3) were excluded
  4. *p < 0.01 vs controls
  5. p < 0.05 vs controls
  6. p < 0.01 vs all MCI patients
  7. $p < 0.01 vs sMCI patients